145218-19-5

Basic information

• Product Name: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)
• Synonyms: Pyridine, 5-bromo-2-(bromomethyl)- (9CI);Pyridine, 5-broMo-2-(broMoMethyl)-;5-Bromo-2-(bromomethyl)
• CAS NO: 145218-19-5
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 250.9186
• Product Categories: PYRIDINE
• Mol File: 145218-19-5.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 109℃
• Appearance: /
• Density: 1.955
• Vapor Pressure: 0.025mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.08±0.22(Predicted)
• CAS DataBase Reference: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)(145218-19-5)
• EPA Substance Registry System: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)(145218-19-5)

Safety Data

• Hazardous Substances Data: 145218-19-5(Hazardous Substances Data)

Usage

General Description

Pyridine, 5-bromo-2-(bromomethyl)- (9CI) is a chemical compound with the molecular formula C6H5Br2N. It is a derivative of pyridine with a bromine atom at the 5th position and a bromomethyl group at the 2nd position. Pyridine, 5-bromo-2-(bromomethyl)- (9CI) is commonly used in organic synthesis as a building block for the construction of various chemical compounds. It is also used in the pharmaceutical industry as an intermediate for the synthesis of drugs and other bioactive molecules. Pyridine, 5-bromo-2-(bromomethyl)- (9CI) is known for its potential as a reagent in chemical reactions and its importance in the development of new chemical compounds. However, it is important to handle this chemical with caution due to its potential health hazards and its reactivity.

InChI:InChI=1/C6H5Br2N/c7-3-6-2-1-5(8)4-9-6/h1-2,4H,3H2

Upstream product

• 97483-77-7 2-Cyano-5-bromopyridine 
• 88139-91-7 (5-bromopyridin-2-yl)methanol 
• 380893-61-8 (5-bromopyridin-2-yl)methyl methanesulfonate 
• 3430-13-5 5-bromo-2-methylpyridine 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 792187-67-8 5-(bromomethyl)-2-methylpyridine 

Downstream Products

• 168823-76-5 5-bromo-2-(chloromethyl)pyridine 
• 1419605-01-8 N-(diphenylmethylene)-6-(methylsulfonylmethyl)pyridin-3-amine 
• 1419605-05-2 phenyl 6-(methylsulfonylmethyl)pyridin-3-ylcarbamate 
• 1419605-07-4 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(methylsulfonylmethyl)pyridin-3-yl)urea 
• 1584732-31-9 tert-butyl 2-(6-(((3R,5R,6S)-1-((S)-2-(tert-butylsulfonyl)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)methyl)pyridin-3-yl)acetate 
• 1584732-30-8 tert-butyl 2-(6-(((3R,5R,6S)-1-((S)-2-(tert-butylthio)-1-cyclopropylethyl)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxopiperidin-3-yl)methyl)pyridin-3-yl)acetate 
• 1180132-76-6 6-((4-methylpiperazin-1-yl)methyl)pyridin-3-amine 

Relevant articles and documents

COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF

A compound of formula (I), a preparation method therefor, a pharmaceutical composition containing a derivative thereof, and the therapeutic uses thereof, especially inhibiting PGE2/EP4 signalling transduction and the uses thereof for treating cancer, acute or chronic pain, migraine, osteoarthritis, rheumatoid arthritis, gout, bursitis, ankylosing spondylitis, primary dysmenorrhea, tumour or arteriosclerosis.

COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Described herein are compounds that act as CYP46A1 inhibitors, compositions comprising these compounds, and methods of their use into treating neurodegenerative diseases and the like, or a pharmaceutically active salt thereof. The present invention relates to compounds represented by the formula wherein each symbol is as defined in the specification, or a pharmaceutically active salt thereof.

5-(PYRIMIDIN-4-YL)-2-(PYRROLIDIN-1-YL)NICOTINONITRILE COMPOUNDS AS IKKE, TBK1 AND/OR SIK2 KINASES INHIBITORS

The invention provides compounds of formula (I) wherein R is ?CH3 or ?CH2CH3 and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of diseases or disorders mediated by IKKE, TBK1 and/or SIK2 mechanisms in a subject, for example cancer and inflammatory and tissue repair disorders. The invention also provides uses of the compounds of formula (I) and compositions containing them. (Formula (I))